Drugs / INCB160058
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06313593 | Aug 2024 → Oct 2028 expected | myeloproliferative neoplasm | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT06213818 | Mar 2024 → Aug 2025 | — | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB160058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06313593 ↗ |
| Route | Oral | “Oral; Immediate release solid tablet” NCT06213818 ↗ |